세계의 천식 및 만성 폐쇄성 폐질환(COPD) 치료제 시장 보고서(2025년)

Asthma and chronic obstructive pulmonary disease (COPD) medications are utilized to control and treat respiratory disorders that lead to breathing difficulties. These medications function by alleviating inflammation, relaxing the muscles in the airways, and enhancing airflow to the lungs, which helps relieve symptoms like shortness of breath, coughing, and wheezing. They are most commonly delivered through inhalers or nebulizers to ensure effective administration directly to the lungs.

The primary categories of drugs used for treating asthma and COPD include bronchodilators, corticosteroids, combination therapies, and leukotriene modifiers. Bronchodilators act rapidly to relax airway muscles, thereby opening the airways and offering quick relief from symptoms associated with asthma and COPD. These medications are administered through multiple methods, such as inhalation, oral tablets, injections, nasal sprays, and others. They are prescribed for a range of patient populations including adults, children, and the elderly, and are employed in treating various conditions such as asthma, COPD, allergic rhinitis, and pulmonary hypertension. The distribution of these medications occurs via multiple channels, including hospital pharmacies, retail outlets, online platforms, and drugstores.

The asthma and COPD drugs market research report is one of a series of new reports from The Business Research Company that provides asthma and COPD drugs market statistics, including the asthma and COPD drugs industry global market size, regional shares, competitors with the asthma and COPD drugs market share, detailed asthma and COPD drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the asthma and COPD drugs industry. This asthma and COPD drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The asthma and COPD drugs market size has grown strongly in recent years. It will grow from $32.52 billion in 2024 to $35.66 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. This growth during the historical period is primarily attributed to increasing levels of air pollution, a rise in smoking habits, heightened awareness of respiratory illnesses, growing usage of corticosteroids and bronchodilators, and an increase in healthcare spending.

The asthma and COPD drugs market size is expected to see strong growth in the next few years. It will grow to $50.99 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. This anticipated growth is driven by the rising preference for personalized treatment approaches, the growing use of biologics and next-generation therapies, a surge in environmental allergy cases, expansion in clinical trials and regulatory approvals, and the increasing prevalence of chronic non-communicable diseases. Notable trends projected during the forecast period include the emergence of smart inhaler technologies, development of dual-action bronchodilators, integration of drug data with electronic health records (EHRs), advancements in biopharmaceutical innovations, and the application of machine learning in the drug development process.

Major players in the asthma and COPD drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. (Roche), Merck & Co. Inc., Sanofi, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc (GSK), Eli Lilly and Company, Amgen, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma, AptarGroup, Chiesi Farmaceutici S.p.A., Dr. Reddy's Laboratories, Cipla Inc., Lupin Limited, Zydus Cadila, Glenmark Pharmaceuticals, Vectura Group, and Aurobindo Pharma.

North America was the largest region in the asthma and COPD drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in asthma and COPD drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the asthma and COPD drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The asthma and COPD drugs market consists of sales of bronchodilators, inhaled corticosteroids, combination inhalers, leukotriene modifiers, biologics, theophylline, and systemic corticosteroids. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on asthma and chronic obstructive pulmonary disease (copd) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for asthma and chronic obstructive pulmonary disease (copd) drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The asthma and chronic obstructive pulmonary disease (copd) drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Bronchodilators; Corticosteroids; Combination Drugs; Leukotriene Modifiers
• 2) By Route Of Administration: Inhalation; Oral; Injection; Nasal; Other Route Of Administrations
• 3) By Patient Group: Adult; Pediatric; Geriatric
• 4) By Application: Asthma; Chronic Obstructive Pulmonary Disease; Allergic Rhinitis; Pulmonary Hypertension
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Drug Stores

Subsegments

• 1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA); Long-Acting Beta-2 Agonists (LABA); Anticholinergics; Long-Acting Muscarinic Antagonists; Methylxanthines
• 2) By Corticosteroids: Inhaled Corticosteroids (ICS); Oral Corticosteroids; Intravenous Corticosteroids
• 3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid; Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist; Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid
• 4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists; Leukotriene Synthesis Inhibitors
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd. (Roche); Merck & Co. Inc.; Sanofi
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Characteristics

3. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Trends And Strategies

4. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Growth Rate Analysis
• 5.4. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Total Addressable Market (TAM)

6. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Segmentation

• 6.1. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bronchodilators
• Corticosteroids
• Combination Drugs
• Leukotriene Modifiers
• 6.2. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhalation
• Oral
• Injection
• Nasal
• Other Route Of Administrations
• 6.3. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult
• Pediatric
• Geriatric
• 6.4. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asthma
• Chronic Obstructive Pulmonary Disease
• Allergic Rhinitis
• Pulmonary Hypertension
• 6.5. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• 6.6. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Sub-Segmentation Of Bronchodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Short-Acting Beta-2 Agonists (SABA)
• Long-Acting Beta-2 Agonists (LABA)
• Anticholinergics
• Long-Acting Muscarinic Antagonists
• Methylxanthines
• 6.7. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhaled Corticosteroids (ICS)
• Oral Corticosteroids
• Intravenous Corticosteroids
• 6.8. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Sub-Segmentation Of Combination Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Long-Acting Beta-Agonist + Inhaled Corticosteroid
• Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist
• Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid
• 6.9. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Sub-Segmentation Of Leukotriene Modifiers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leukotriene Receptor Antagonists
• Leukotriene Synthesis Inhibitors

7. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Regional And Country Analysis

• 7.1. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 8.1. Asia-Pacific Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 9.1. China Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
• 9.2. China Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 10.1. India Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 11.1. Japan Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
• 11.2. Japan Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 12.1. Australia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 13.1. Indonesia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 14.1. South Korea Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
• 14.2. South Korea Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 15.1. Western Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
• 15.2. Western Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 16.1. UK Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 17.1. Germany Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 18.1. France Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 19.1. Italy Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 20.1. Spain Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 21.1. Eastern Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
• 21.2. Eastern Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 22.1. Russia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 23.1. North America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
• 23.2. North America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 24.1. USA Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
• 24.2. USA Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 25.1. Canada Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
• 25.2. Canada Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 26.1. South America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
• 26.2. South America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 27.1. Brazil Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 28.1. Middle East Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
• 28.2. Middle East Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

• 29.1. Africa Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
• 29.2. Africa Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Competitive Landscape And Company Profiles

• 30.1. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Competitive Landscape
• 30.2. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. (Roche) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi Overview, Products and Services, Strategy and Financial Analysis

31. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Other Major And Innovative Companies

• 31.1. AstraZeneca Plc
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline Plc (GSK)
• 31.4. Eli Lilly and Company
• 31.5. Amgen
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Boehringer Ingelheim
• 31.8. Astellas Pharma
• 31.9. AptarGroup
• 31.10. Chiesi Farmaceutici S.p.A.
• 31.11. Dr. Reddy's Laboratories
• 31.12. Cipla Inc.
• 31.13. Lupin Limited
• 31.14. Zydus Cadila
• 31.15. Glenmark Pharmaceuticals

32. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

34. Recent Developments In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

35. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer